WuXi Biologics (Cayman) Inc.

Equities

2269

KYG970081173

Pharmaceuticals

Market Closed - Hong Kong S.E. 04:08:03 2024-03-28 am EDT 5-day change 1st Jan Change
14.3 HKD +3.92% Intraday chart for WuXi Biologics (Cayman) Inc. +0.70% -51.69%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
WuXi Biologics' 2023 Profit Falls 23% Despite Revenue Jump MT
WuXi Biologics 2023 Net Profit Fell on Higher Expenses, Impairment Losses DJ
WuXi Biologics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Hong Kong Shares Slip Amid Downbeat Earnings, Cautious Trade MT
WuXi AppTec's Shares Fall After Downbeat Guidance DJ
WuXi AppTec's Net Profit Jumps, Reiterates It Doesn't Pose Security Threat DJ
WuXi Biologics Inc.(SEHK:2269) dropped from S&P International 700 CI
WuXi Biologics Inc.(SEHK:2269) dropped from S&P Global 1200 CI
Hong Kong Shares Drop as PBoC Keeps Key Policy Rate Unchanged MT
WuXi Shares Fall as Washington Lobbying Group Cuts Ties DJ
China stocks steady, helped by biotech rally; Wuxi Apptec drags Hong Kong shares RE
Biotech trade association to split with China's WuXi AppTec RE
Huanghe Whirlwind Names Chairman, Vice Chairman MT
WuXi AppTec 'Strongly Disagrees' With US Draft Bill Amid Share Slump MT
WuXi Biologics Refutes Ties With WuXi AppTec Amid Stock Slump MT
Hong Kong Shares Drop as US Bill Fixes On Chinese Biotech Firms MT
WuXi Companies' Shares Fall Amid Renewed U.S. Sanction Concerns DJ
Hong Kong Shares Advance as Traders Eye Earnings Data; JD.com Rises 8% MT
WuXi Companies' Shares Rise on Receding Worries About Potential U.S. Sanctions DJ
Nomura Adjusts Wuxi Biologics' Price Target to HK$53.65 From HK$58.44, Keeps at Buy MT
China stocks set to snap nine-session winning run, HK shares also down RE
Hong Kong stocks rise, China markets reopen next week after Lunar New Year break RE
WuXi Shares Hit by U.S. Committee Seeking Inquiry, Blacklisting DJ
Wuxi Biologics Says It Is Not a Wuxi AppTec Subsidiary Amid US Security Risk Probe MT
US Lawmakers Urge Review of China’s Wuxi AppTec, Wuxio Biologics for Possible Sanctions MT
Chart WuXi Biologics (Cayman) Inc.
More charts
WuXi Biologics Cayman Inc is an investment holding company principally engaged in provision of discovery, development and manufacturing services of biologics. Through fully-integrated biologics Contract Research, Development and Manufacturing Organization (CRDMO), the Company provides one-stop end-to-end biologics services. Biologics development process stages include pre-IND (drug discovery and pre-clinical development), early-phase (phases I & II) clinical development, late-phase (phase III) clinical development and commercial manufacturing. The Company also offers end-to-end vaccine CRDMO services, including vaccine discovery and development, scale-up commercial manufacturing and global distribution. The Company has WuXiBody bispecific antibody platform, SDArBodY multispecific antibody platform, WuXia cell line development platform, WuXiUP continuous manufacturing platform and mRNA vaccine platform. The Company mainly operates its businesses in the domestic and overseas markets.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
A-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
32
Last Close Price
12.71 CNY
Average target price
37.4 CNY
Spread / Average Target
+194.23%
Consensus

Quarterly revenue - Rate of surprise

  1. Stock
  2. Equities
  3. Stock WuXi Biologics (Cayman) Inc. - Hong Kong S.E.
  4. News WuXi Biologics (Cayman) Inc.
  5. Wuxi Biologics Repurchases Nearly $503 Million Worth of Shares; Shares Fall 7%